Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
John H. Strickler(Duke Medical Center), Marc Van den Evnde, Benoist Chibaudel, Andrew Scott Paulson(Texas Oncology), Joleen M. Hubbard(Rutgers, The State University of New Jersey), Christophe Borg(Centre Hospitalier Universitaire de Besançon), Matthieu Sarabi, Marc Peeters(University of Antwerp), Christina Wu(Mayo Clinic Hospital), Elena Élez(Vall d'Hebron Hospital Universitari), Salvatore Siena(University of Milan), Andrea Cercek(Memorial Sloan Kettering Cancer Center), Christos Fountzilas(Roswell Park Comprehensive Cancer Center), Ramón Salazar(Institut Català d'Oncologia), Federico Sanchez, François Ghiringhelli(Inserm), Adel Kardosh(Oregon Health & Science University), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Kristen K. Ciombor(The Ohio State University), Michael Stecher(Seagen (United States)), Andrew L. Coveler(University of Washington), Wentao Feng(Seagen (United States)), Pilar Alfonso, Tanios Bekaii‐Saab(WinnMed), Kimmie Ng(Dana-Farber Cancer Institute), Pashtoon Murtaza Kasi(Cornell University), David L. Bajor(University Hospitals of Cleveland), Thierry André(Inserm), Chiara Cremolini(University of Pisa), Maria Giulia Zampino(Azienda Ospedaliera Universitaria Pisana), Susana R. Keranen(Universitat Autònoma de Barcelona), Eric Van Cutsem(Universitair Ziekenhuis Leuven)
Cited by 244
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k